MapLight Therapeutics Inc. (Ticker: MPLT US) is a U.S.-based clinical-stage biopharmaceutical company developing treatments for central nervous system (CNS) disorders. MapLight plans to list on the NASDAQ Global Market on October 28, 2025, offering 14.75 million common shares at $17.00 per share, to raise approximately $250.75 million. The IPO is managed by Morgan Stanley & Co. (Left Lead), Jefferies LLC, Leerink Partners LLC, and Stifel Nicolaus & Co. Inc.. Founded in 2018 and incorporated in Delaware, the company focuses on developing circuit-specific pharmacotherapies, with its lead candidate ML-007C-MA targeting schizophrenia and Alzheimer’s disease psychosis. The offering includes a 15% greenshoe option (2.21 million shares). Notably, the IPO was priced under the “20-day registration rule” during the U.S. government shutdown, locking in its price without SEC approval.